London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Suthy, I can’t understand why they originally wrote $6m to be received by end of 2023 if it wasn’t set in stone. The wording now is not even confident they will receive the $5.5m by end of 2024, it is simply worded as “ Up to $5.5m in further milestones expected within 2024”. What exactly does that mean?
I do agree with flashgarden, EVG need to find a way to generate income to fund the company. Getting grants for clinical trials or partnerships with other pharmas is great but these things obviously take years before any money starts to roll in. How can any business run without money coming in?
Cj39- that move is a classic one when they have no clue when the money will be received.
Brutal assessment but sometimes I do get the feeling that the management are transfixed by the biology when their primary focus should be on money.
She could have signed up 100 Stalicla deals, it hasn't stopped the share price hitting new lows so in my eyes she has done nothing to add to share holder value.
Pretty sure it was Dr Helen Kuhlman who landed the Stalicla deal
We are paying Dr Helen Kuhlman all this money and all she can show for her extortionate salary is a small article in some obscure medical journal.
Still, at least some is making money out of Evgen, we're not all losers.
King -yes not sure i would call this a spike, more of a small blip. Can see this drifting lower now ....
Would not surprise me to see this drop to 1.4p
I was hoping any spike would close the 3.02 gap.
Oh well back to drifting lower I suppose.
At least I now know what the coating on the tablet is for.
CJ, Thanks for the clarification.
Bobsson, that guidance changed in the full year results to: o Up to $5.5m in further milestones expected within 2024.
They shifted the goal posts from $5.5m will be received by end of 2023 to now being expected in 2024 but no time scale.
Just reviewed the RNS dated 10/10/2022 announcing the Stalicla collaboration, and the timetable for progression. The SFX enteric coated tablet development was a success RNS 22/3/2023. The human volunteer Phase 1 study using the EC tablet was a success RNS 15/8/2023. Therefore looks to me as if a milestone payment of $0.5m is due from Stalicla? Also $5 million is due as a milestone payment if the FDA grants Investigational New Drug (IND) status to Stalicla. We should expect these payments before the end of 2023?
A good summing up, thanks.
I think it all lies on the Stalicla deal and the money being received in time to avert a share placing. But the bizarre thing also is, Stalicla have a deal to pay EVG $160m in milestone payments if all goes to plan but EVG is currently only worth about £5m, surely Stalicla will just buy EVG out of the drug is effective for them meaning all this potential money is unlikely to ever be seen by EVG shareholders.
With regards to SFX-01 being a food supplement, wasn’t that what Juvenesense were planning SFX-01 for and they pulled the plug before it even materialised? No mention why. Was it not effective?
I don’t see any immediate sources of money likely from anywhere other than possibly Stalicla. Any deals EVG get like Stalicla was only £0.5m up front, such sums of money are simply not enough.
What shareholders need to know here is how the company will be funded over the next few years. And is it really worth investing if it’s going to be years before any real significant money will be realised?
Yet.....imo.
Indeed. Not least putting their hand in their pockets to buy (more than just) a few on the open market.
Another thing I have mentioned repeatedly.
But pleased with the update today, so let us bask in something positive here, for a change :)
In the last 12 months they have done 4 InvestorMeet presentationa/q&a's which is a big improvement to previous years (when they did virtually no presentations/promotion).
But yes still plenty of room for improvement.
Frankly, I do not care. On AIM, and in this current climate especially, I want to see significantly more marketing and face time by the BOD and other relevant employees.
Something that I have been repeatedly banging the drum about for over a year now.
It is IMO naive in the extreme to not understand that, even if the pipeline is exciting and works, the BOD simply cannot let the science do the talking alone.
Especially taking into consideration their remuneration.
Anyway, as I said before, let us hope this is just the start of a lot of positive information that will hopefully generate plenty of new investor interest, and either stop the stale bulls from selling up further - or at least clear them out quicker.
"The future clinical development of SFX-01 is highly exciting"
But not exciting enough for the bods to dip into their own pockets.
Agree it's hard to know who the intended audience is. I would guess this is the sort of magazine that pharma companies might put in their canteen for employees to read on their lunchbreak.
Yes but the letter interests me. Who is it aimed at and why a letter from the Business Manager and not one of the key scientists? I wondered if there had been a shift in their agenda? Probably I am the only one here who thought it odd. While I stop lossed some weeks back the science here interests me and I like to keep an eye on the ones that got away because sometimes they come good after a period in sp purgatory.
Didn't you used to be a holder here?
As you know they are focusing on the pharmaceutical applications (agreement with Juvenescence for the neutraceutical side was ended earlier this year), of which the foremost are oncology and neurological disorders - clinical trials for both of these areas are anticipated in the next months. Licence deal with Stalicla for the latter.
Interested in the RNS and article by the new biz manager.
My question is this. Is this product going to be an FDA approved oncology drug or.......a food supplement one can safely take which might boost the body's immune system against cancer? I am inclined to think the path to profit faster via the second option than the first.
Leaky ship, this one it seems.
Anyway, good to see an update after so long a period of radio silence.
Hopefully the start of a more positive period of news flow here. GLA.
Not sure I fully agree with that king alf. Every day is a reset. His decisions will be based on where he thinks it is going from this point forwards. However I do think you are right about a spike being due.
Probably similar to a lot of other holders who got in around the 8p range, currently sitting on a 79% paper loss. You've lost so much already it's hardly worth realizing your loss, he'll stick with it as the only thing left now is hope.